Home ›
NPI 1952328569
NPI deactivated
1952328569
1952328569 was paid $11.03M by Medicaid between Jan 2018 and Aug 2022, across 179 billing codes. Its largest line is 99284, emergency room visit (serious) — 18% of everything it billed.
33Billing provider info1952328569
33aNPI1952328569
33bProvider type—
28Total paid$11.03M
24GClaims196,982
24DCodes billed179
24AFirst – last monthJan 2018 – Aug 2022
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 85,756 | $5.03M | |
| 2019 | 94,276 | $5.24M | |
| 2020 | 6,818 | $265K | |
| 2021 | 6,863 | $323K | |
| 2022 | 3,269 | $167K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 18% | 3,861 | 2,824 | $1.96M |
| G0378 | Hospital observation service, per hour | 14% | 706 | 500 | $1.51M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.1% | 2,372 | 1,922 | $568K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.2% | 5,553 | 4,318 | $460K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.0% | 482 | 344 | $444K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.0% | 5,213 | 4,020 | $436K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.5% | 2,237 | 1,332 | $385K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.0% | 2,609 | 1,598 | $327K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.3% | 3,537 | 3,132 | $256K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.2% | 3,824 | 3,039 | $238K |
| 80061 | Lipid panel | 2.0% | 7,812 | 6,159 | $221K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.8% | 5,521 | 4,391 | $195K |
167 more codes
| 80053 | Comprehensive metabolic panel | 1.7% | 6,235 | $190K |
| 80050 | General health panel | 1.7% | 2,664 | $190K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 10,504 | $173K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.5% | 2,297 | $170K |
| 87481 | 1.5% | 844 | $169K | |
| 36415 | Collection of venous blood by venipuncture | 1.3% | 32,488 | $148K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 1.2% | 2,636 | $129K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 1.1% | 849 | $124K |
| 87536 | 1.0% | 655 | $116K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,762 | $97K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,901 | $94K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,242 | $87K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 863 | $77K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 1,303 | $72K |
| 93017 | <1% | 296 | $71K | |
| 86780 | <1% | 2,328 | $69K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,999 | $67K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 905 | $66K |
| 86803 | <1% | 2,110 | $63K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 313 | $60K |
| 87522 | Neg quan hep c or qual rna | <1% | 659 | $59K |
| 86003 | <1% | 236 | $54K | |
| 82607 | <1% | 1,502 | $48K | |
| 85027 | <1% | 3,353 | $46K | |
| 82728 | <1% | 1,602 | $46K | |
| 84403 | <1% | 789 | $42K | |
| 83013 | <1% | 274 | $38K | |
| 86480 | <1% | 288 | $37K | |
| 86360 | <1% | 339 | $33K | |
| 83655 | <1% | 1,314 | $32K | |
| 80076 | <1% | 1,836 | $32K | |
| 87480 | <1% | 756 | $32K | |
| 87510 | <1% | 753 | $31K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 383 | $31K |
| 87660 | <1% | 752 | $31K | |
| 84153 | <1% | 807 | $31K | |
| 86618 | <1% | 865 | $31K | |
| 87340 | <1% | 1,401 | $30K | |
| 84439 | <1% | 1,578 | $30K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 314 | $28K |
| 82565 | <1% | 2,451 | $26K | |
| 86359 | <1% | 338 | $26K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 145 | $26K |
| 85610 | <1% | 3,035 | $25K | |
| 86481 | <1% | 153 | $24K | |
| 97803 | <1% | 311 | $22K | |
| 86617 | <1% | 336 | $22K | |
| 86706 | <1% | 963 | $21K | |
| 83516 | <1% | 620 | $21K | |
| 83970 | <1% | 248 | $21K | |
| 81001 | <1% | 3,118 | $21K | |
| 84270 | <1% | 458 | $21K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 39 | $20K |
| 86038 | <1% | 737 | $18K | |
| 82248 | <1% | 1,693 | $18K | |
| 87088 | <1% | 1,037 | $17K | |
| 84460 | <1% | 1,555 | $17K | |
| 83540 | <1% | 1,266 | $17K | |
| 82670 | <1% | 289 | $17K | |
| 86140 | <1% | 1,525 | $16K | |
| 84450 | <1% | 1,521 | $16K | |
| 87186 | <1% | 871 | $16K | |
| 83550 | <1% | 872 | $16K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 171 | $15K |
| 85651 | <1% | 2,061 | $15K | |
| 86762 | <1% | 499 | $15K | |
| 86704 | <1% | 582 | $15K | |
| 87077 | <1% | 731 | $14K | |
| 82043 | <1% | 1,191 | $14K | |
| 80051 | <1% | 978 | $14K | |
| 83735 | <1% | 993 | $14K | |
| 82746 | <1% | 461 | $14K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 19 | $14K |
| 84481 | <1% | 371 | $13K | |
| 80074 | <1% | 128 | $13K | |
| 83001 | <1% | 328 | $13K | |
| 84702 | <1% | 390 | $13K | |
| 86787 | <1% | 455 | $12K | |
| 86235 | <1% | 111 | $12K | |
| 84520 | <1% | 1,433 | $12K | |
| 86665 | <1% | 153 | $12K | |
| 84146 | <1% | 287 | $11K | |
| 82784 | <1% | 411 | $10K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 24 | $10K |
| 84480 | <1% | 336 | $10K | |
| 87070 | <1% | 526 | $9K | |
| 84425 | <1% | 214 | $9K | |
| 86696 | <1% | 141 | $9K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 48 | $8K |
| 83721 | <1% | 421 | $8K | |
| 83002 | <1% | 210 | $8K | |
| 97804 | <1% | 112 | $8K | |
| 81003 | <1% | 1,534 | $8K | |
| 82570 | <1% | 701 | $8K | |
| 82040 | <1% | 726 | $7K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 43 | $7K |
| 87902 | <1% | 13 | $7K | |
| 82550 | <1% | 484 | $7K | |
| 86708 | <1% | 253 | $6K | |
| 86765 | <1% | 231 | $6K | |
| 82947 | <1% | 749 | $6K | |
| 83690 | <1% | 407 | $6K | |
| 86431 | <1% | 511 | $6K | |
| 86735 | <1% | 212 | $6K | |
| 86160 | <1% | 129 | $6K | |
| 87640 | <1% | 81 | $6K | |
| 84100 | <1% | 574 | $6K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 57 | $6K |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 165 | $5K |
| 86200 | <1% | 196 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 50 | $5K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 154 | $5K |
| 86664 | <1% | 150 | $5K | |
| 84550 | <1% | 483 | $5K | |
| 86039 | <1% | 188 | $4K | |
| 86666 | <1% | 79 | $4K | |
| 87641 | <1% | 59 | $4K | |
| 87205 | <1% | 454 | $4K | |
| 86663 | <1% | 150 | $4K | |
| 83020 | <1% | 148 | $4K | |
| 82310 | <1% | 373 | $4K | |
| 86753 | <1% | 78 | $4K | |
| 84703 | <1% | 249 | $4K | |
| 86695 | <1% | 84 | $4K | |
| 87529 | <1% | 27 | $4K | |
| 82465 | <1% | 386 | $3K | |
| 83718 | <1% | 203 | $3K | |
| 82652 | <1% | 43 | $3K | |
| 83615 | <1% | 269 | $3K | |
| 84134 | <1% | 106 | $3K | |
| 0002A | <1% | 77 | $3K | |
| 86225 | <1% | 108 | $3K | |
| 93299 | <1% | 12 | $3K | |
| 85007 | <1% | 402 | $3K | |
| 85730 | <1% | 221 | $3K | |
| 82785 | <1% | 79 | $3K | |
| 82150 | <1% | 188 | $3K | |
| 82950 | <1% | 197 | $2K | |
| 84156 | <1% | 245 | $2K | |
| 83993 | <1% | 46 | $2K | |
| 86256 | <1% | 74 | $2K | |
| 87650 | <1% | 40 | $2K | |
| 86850 | <1% | 222 | $2K | |
| 86376 | <1% | 54 | $2K | |
| 85018 | <1% | 325 | $2K | |
| 85014 | <1% | 324 | $2K | |
| 86901 | <1% | 254 | $2K | |
| 86900 | <1% | 254 | $2K | |
| 84075 | <1% | 120 | $1K | |
| 82105 | <1% | 35 | $1K | |
| 97161 | <1% | 13 | $1K | |
| 85045 | <1% | 131 | $1K | |
| 84436 | <1% | 73 | $1K | |
| 80164 | <1% | 34 | $1K | |
| 84478 | <1% | 73 | $877.31 | |
| 81025 | <1% | 67 | $871.67 | |
| 80178 | <1% | 64 | $871.04 | |
| 86308 | <1% | 64 | $681.60 | |
| 86592 | <1% | 70 | $629.54 | |
| 84132 | <1% | 59 | $568.93 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 18 | $443.88 |
| 82533 | <1% | 12 | $436.02 | |
| 82977 | <1% | 27 | $402.00 | |
| 84165 | <1% | 17 | $375.70 | |
| 83525 | <1% | 16 | $363.16 | |
| 0001A | <1% | 44 | $359.04 | |
| 84155 | <1% | 36 | $271.80 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.